在全身性硬化症治疗中使用托西利祖马布:一个病例报告
Maysoun Kudsi1, Naram Khalayli1, Raghad Tarcha1
1Faculty of Medicine, Damascus University.
托西利祖马布治疗对全身性硬化症有希望,维持肺功能和改善皮肤纤维化. 这种生物疗法似乎是安全有效的,预示着硬化皮肤病管理的新时代.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
背景情况:
- 系统性硬化症是一种慢性自身免疫性疾病,其特征是皮肤和内脏器官,包括肺部的纤维化.
- 间歇性肺病 (ILD) 是系统性硬化症的常见和严重并发症,导致显著的发病率和死亡率.
- 托西利祖马布 (tocilizumab) 是一种干白素-6受体抑制剂,因其在自身免疫和炎症疾病中的潜在治疗益处而引起了人们的注意.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
12:36Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cystic Fibrosis: Management
Sinus disease and chronic...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Drugs for Treatment of Ulcerative Colitis in IBD
